Neuropathy associated with IgM paraproteinemia
(See separate entry for Axonal neuropathy associated with IgM paraproteinemia)
Recommended Indications in which IG can be used
Order Number: N10-NAIgMP
| Recommendations | Demyelinating neuropathy associated with IgM paraproteinemia, without anti-MAG antibodies IVIG is recommended for neuropathy associated with IgM, with clinical and electrophysiological features consistent with CIDP, in the absence of anti-MAG antibodies. |
| Dose/Frequency of Administration | 2 g/kg adjusted body weight divided over 2 to 5 days, every 4 weeks. IVIG should be administered for 3 to 6 months to assess efficacy. Some patients do not show a definitive sustained response until they have undergone up to 6 treatment cycles. Once the patient’s condition has stabilized, consider titrating the dose and/or the treatment interval to the lowest dose necessary to maintain clinical effectiveness. |